Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.

Phillips K, Cirrone F, Ahuja T, Siegfried J, Papadopoulos J.

J Oncol Pharm Pract. 2019 Mar;25(2):398-403. doi: 10.1177/1078155218806975. Epub 2018 Oct 14.

PMID:
30319061
2.

Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.

Ananda-Rajah MR, Grigg A, Downey MT, Bajel A, Spelman T, Cheng A, Thursky KT, Vincent J, Slavin MA.

Haematologica. 2012 Mar;97(3):459-63. doi: 10.3324/haematol.2011.051995. Epub 2011 Nov 4.

3.

Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).

Mellinghoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M, Hasenkamp J, Kiehl M, Koldehoff M, Krause SW, Lehners N, von Lilienfeld-Toal M, Löhnert AY, Maschmeyer G, Teschner D, Ullmann AJ, Penack O, Ruhnke M, Mayer K, Ostermann H, Wolf HH, Cornely OA.

Ann Hematol. 2018 Feb;97(2):197-207. doi: 10.1007/s00277-017-3196-2. Epub 2017 Dec 7. Review.

4.

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D.

N Engl J Med. 2007 Jan 25;356(4):348-59.

5.

Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain.

Cámara R, Gozalbo I, Jurado M, Sanz J, Aragón B, Grau S.

Adv Ther. 2017 Sep;34(9):2104-2119. doi: 10.1007/s12325-017-0600-1. Epub 2017 Aug 14.

6.

Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison.

Tormo M, Pérez-Martínez A, Calabuig M, Hernández-Boluda JC, Amat P, Navarro D, Solano C.

Mycoses. 2018 Mar;61(3):206-212. doi: 10.1111/myc.12728. Epub 2018 Jan 3.

PMID:
29125660
7.

Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.

Liebenstein TK, Widmer KM, Fallon MJ.

J Oncol Pharm Pract. 2018 Dec;24(8):599-603. doi: 10.1177/1078155217722405. Epub 2017 Aug 2.

PMID:
28768441
8.

The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.

Barreto JN, Beach CL, Wolf RC, Merten JA, Tosh PK, Wilson JW, Hogan WJ, Litzow MR.

Am J Hematol. 2013 Apr;88(4):283-8. doi: 10.1002/ajh.23388. Epub 2013 Mar 5.

9.
10.

Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.

Hachem R, Assaf A, Numan Y, Shah P, Jiang Y, Chaftari AM, Raad II.

Int J Antimicrob Agents. 2017 Sep;50(3):384-388. doi: 10.1016/j.ijantimicag.2017.03.021. Epub 2017 Jul 8.

PMID:
28694233
11.

Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.

Cho SY, Lee DG, Choi SM, Choi JK, Lee HJ, Kim SH, Park SH, Choi JH, Yoo JH, Kim YJ, Kim HJ, Min WS.

Mycoses. 2015 Sep;58(9):565-71. doi: 10.1111/myc.12357. Epub 2015 Jul 27.

PMID:
26214656
12.

Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.

Cho SY, Lee DG, Choi JK, Lee HJ, Kim SH, Park SH, Choi SM, Choi JH, Yoo JH, Kim YJ, Kim HJ, Min WS, Back H, Kang S, Lee EK.

Clin Ther. 2015 Sep;37(9):2019-27. doi: 10.1016/j.clinthera.2015.06.014. Epub 2015 Jul 15.

13.

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.

Mattiuzzi GN, Cortes J, Alvarado G, Verstovsek S, Koller C, Pierce S, Blamble D, Faderl S, Xiao L, Hernandez M, Kantarjian H.

Support Care Cancer. 2011 Jan;19(1):19-26. doi: 10.1007/s00520-009-0783-3. Epub 2009 Dec 3.

PMID:
19956980
14.

Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.

Solano C, Slavin M, Shaul AJ, Marks DI, Cordonnier C, Cornely OA, Pagliuca A, Cragin L, Jarque I, Garcia-Vidal C, Sorensen S, Vanness DJ, Charbonneau C, Barrueta JA, Peral C, De Salas-Cansado M, Bow EJ.

Mycoses. 2017 Feb;60(2):79-88. doi: 10.1111/myc.12552. Epub 2016 Aug 26.

PMID:
27562016
15.
16.

Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions.

Geist MJP, Egerer G, Mikus G, Blank A, Hohmann N, Heinz WJ, Carls A.

Basic Clin Pharmacol Toxicol. 2019 Jan;124(1):56-61. doi: 10.1111/bcpt.13093. Epub 2018 Aug 2.

PMID:
29989301
17.

Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis.

Zhao YJ, Khoo AL, Tan G, Teng M, Tee C, Tan BH, Ong B, Lim BP, Chai LY.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):376-86. doi: 10.1128/AAC.01985-15. Print 2016 Jan.

18.

Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.

Lundberg J, Höglund M, Björkholm M, Åkerborg Ö.

Clin Drug Investig. 2014 Jul;34(7):483-9. doi: 10.1007/s40261-014-0199-9.

PMID:
24820968
19.

Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.

Busca A, Candoni A, Audisio E, Passera R, Bruno B, Monaco F, Mordini N, Vacca A, Delia M, Aversa F, Pagano L.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2214-2219. doi: 10.1016/j.bbmt.2016.09.019. Epub 2016 Sep 22.

20.

Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.

Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely OA.

Pharmacotherapy. 2008 Oct;28(10):1223-32. doi: 10.1592/phco.28.10.1223.

PMID:
18823218

Supplemental Content

Support Center